Trial Profile
A prospective, one-arm, single-centre, phase II study to evaluate the PI3K/Akt/mTOR clinical genotyping in companion with other clinical variables in patients with metastatic renal cell carcinoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Nov 2015
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Renal cell carcinoma
- Focus Biomarker; Therapeutic Use
- 23 Nov 2015 New trial record